Sold Out
Now more than ever, the world needs innovation in healthcare. Systems are strained, and staff and patients are suffering as a result. The good news is that NZ's healthtech solutions can address the multifaceted challenges of the sector. With an ecosystem of over 260+ firms, plus an active research community and entrepreneurial clinicians, healthtech innovations are being delivered to market, with considerable economic benefit to the country, not to mention improved patient outcomes.
Healthtech is valued at $2.6B in 2023, and is only set to grow. TIN predicts that NZ's largest healthtech firms will surpass $3.5B in revenue by 2028. Outward-facing and globally competitive, NZ’s leading healthtech firms exported 90% of their product in 2023, with 12% of total revenue redeployed into local R&D activities.
The third edition of the New Zealand Healthtech Report is a comprehensive exploration of this crucial sector. It touches on all the key players: with profiles of firms with $5m+ in revenue, case studies of exciting start-ups, a directory of over 100 firms, and an ecosystem of the best and brightest. The report discusses activity across the regions of New Zealand, as well as the most important offshore markets. Plus, an update on the investment environment and key data-driven insights on the wider sector.
Join us at the University of Auckland to hear how innovation and investment today will help cure patients and solve problems tomorrow.
Date:
August 14, 2024
Time:
6:00 pm - 9:00 pm
Location:
Faculty of Engineering, Building 405, Level 3, University of Auckland
5/7 Grafton Road
Auckland 1010
Auckland 1010
Sold Out
Panellists:
Jeff Douglas
Managing Director
Douglas Pharmaceuticals
Jeff Douglas is the Managing Director of Douglas Pharmaceuticals, New Zealand’s largest privately owned pharmaceutical company. Douglas Pharmaceuticals’ focus is on innovation, development and manufacturing and sells 70% of its production offshore.
Natalia Lopez
Kitea Health
COO/Cofounder
Natalia’s career started off in the heavily regulated automotive industry as a systems engineer. This complemented her shift into the life science and medical device industry 10 years ago. She has worked with multiple medical device spinouts to develop their quality systems and to ensure regulatory compliant product development. She now focuses on market entry strategy for the Kitea System.
Kathryn de Ridder
Bridgewest Ventures
Senior Portfolio Investment Manager
Kate de Ridder trained and worked as an Aerospace Engineer, leading large teams on airborne defence force missions for the first half of her career. With a BEng E&E (Hons), MSc Science in Aerospace Vehicle Design, and a PG Bus studies, she transitioned to the world of venture capital. She has helped Bridgewest Ventures New Zealand (BVNZ) build the investment team and a portfolio of deep tech investments including two medtech investments.
Ehsan Vaghefi
Toku Eyes
CEO/Cofounder
Ehsan is Cofounder and CEO of Toku Eyes. He is also an Associate Professor at Auckland University, with a PhD in biomedical engineering. Ehsan has published more than 45 peer reviewed articles, received USD8m in research grants and has so far raised USD12m in VC funding.
Aisling Weir
Buddle Findlay
Special Counsel
Aisling is a Special Counsel at Buddle Findlay and a health technology specialist. She has worked in and around the health sector for the majority of her career, including being in-house at Fisher & Paykel Healthcare, and on long term secondment to Te Whatu Ora – Health NZ. Aisling has specific expertise in the provision of digital health services, the adoption and implementation of AI tools in clinical settings, the commercialisation of medical technology, and the regulation of therapeutic products.
The 2024 New Zealand Healthtech Report is sponsored by:
